Gene therapy of the human retina


Retinal gene therapy holds great promise in treating different forms of non-inherited and inherited blindness . Continue Reading

Gene therapy in Parkinson’s disease


Gene therapy in Parkinson’s disease is a specific neurotransmitter ( dopamine ), protect the neural system, or the modification of genes that are related to the disease. Then these cells are transplanted to a patient with the disease. There are different kinds of treatments that focus on reducing the symptoms of the disease but there is no cure. Continue Reading

Gene therapy for osteoarthritis

Gene transfer strategies for medical management of osteoarthritis have attracted the attention of scientists to the complex pathology of this chronic disease. Unlike other pharmacological treatments, gene therapy targets the disease process rather than the symptoms. [1] Continue Reading

Gene therapy for epilepsy

Gene therapy is being studied for some forms of epilepsy . [1] It relates to viral or non-viral vectors to deliver DNA or RNA to target areas where seizures arise, or to reduce the frequency of seizures . Gene therapy HAS Delivered promising results in early stage clinical trials for other neurological disorders Such As Parkinson’s disease , [2] raising the Hope that it will Become a treatment for intractable epilepsy . Continue Reading

Gene therapy for color blindness

Gene therapy for color blindness is an experimental gene therapy aiming to convert congenitally colorblinds to trichromats by introducing a photopigment gene that they lack. Though partial color blindness is considered to be a disadvantage, it is a condition that affects many people, particularly males . Complete color blindness, or achromatopsia , is very rare but more severe. While never shown in humans, animal studies have shown that it is possible to confer color by injecting a gene of the missing photopigment using gene therapy. As of 2014, there is no medical entity providing this treatment, and no clinical trials available for volunteers. Continue Reading

European Society of Gene and Cell Therapy

The European Society of Gene and Cell Therapy ( ESGCT ) is a non-profit organization for educational and scientific purposes. The aim of ESGCT is to promote fundamental and clinical research in gene therapy , cell therapy , and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe. Continue Reading

Antisense therapy

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a Particular gene is Known to be causative of a Particular disease, it is feasible to synthesize a strand of nucleic acid ( DNA, RNA or a similar chemical) That will bind to the messenger RNA (mRNA) produced by That gene and inactivate it, effectively turning that gene “off”. This is because mRNA has been translated. Alternatively, the strand might be targeted to a splicing site on pre-mRNA and modify the exon content of an mRNA. [1] Continue Reading

2002 French gene therapy trials

The 2002 French gene therapy trials Were experimental gene therapy trials Performed on children Suffering from Severe Combined Immune Deficiency (SCID). The trials Were based in Paris and lead by Researchers Alain Fischer and Marina Cavazzana Calvo. Whilst the experiment INITIALLY Seemed successful, Many of the Children Began showing symptoms of various cancer -like diseases as a result of the gene manipulation. The experiment, and others like it, were more shut down. Continue Reading